RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-9
Abstract
Since its identification, the RANKL cytokine has been demonstrated to play a crucial role in bone homeostasis and lymphoid tissue organization. Genetic defects impairing its function lead to a peculiar form of autosomal recessive osteopetrosis (ARO), a rare genetic bone disease presenting early in life and characterized by increased bone density due to failure in bone resorption by the osteoclasts. Hematopoietic stem cell transplantation (HSCT) is the only option for the majority of patients affected by this life-threatening disease. However, the RANKL-dependent ARO does not gain any benefit from this approach, because the genetic defect is not intrinsic to the hematopoietic osteoclast lineage but rather to the mesenchymal one. Of note, we recently provided proof of concept of the efficacy of a pharmacological RANKL-based therapy to cure this form of the disease. Here we provide an overview of the diverse roles of RANKL in the bone and immune systems and review the clinical features of RANKL-deficient ARO patients and the results of our preclinical studies. We emphasize that these patients present a continuous worsening of the disease in the absence of a cure and strongly wish that the therapy we propose will be further developed.Keywords
Funding Information
- Fondazione Telethon (GGP12178, GR-2008-1134625)
- Ministero della Salute (GGP12178, GR-2008-1134625)
This publication has 75 references indexed in Scilit:
- Dynamic visualization of RANKL and Th17-mediated osteoclast functionJournal of Clinical Investigation, 2013
- Osteocyte RANKL: New insights into the control of bone remodelingJournal of Bone and Mineral Research, 2012
- Distinct Developmental Requirements for Isolated Lymphoid Follicle Formation in the Small and Large IntestineThe American Journal of Pathology, 2011
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisProceedings of the National Academy of Sciences, 2010
- Control of RANKL gene expressionBone, 2010
- Expression of receptor activator of nuclear factor‐κB ligand by B cells in response to oral bacteriaOral Microbiology and Immunology, 2009
- Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-κB Ligand Gene Reduces Bone Remodeling and Increases Bone MassEndocrinology, 2007
- RANK signals from CD4+3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medullaJournal of Experimental Medicine, 2007
- Parathyroid Hormone Controls Receptor Activator of NF-κB Ligand Gene Expression via a Distant Transcriptional EnhancerMolecular and Cellular Biology, 2006